The Biden administration has set wheels in motion to evaluate and possibly reverse a series of maneuvers imposed by the Trump administration that limited FDA’s authority, reduced its ability to function, and exposed career staff...

OrbiMed Advisors continued to lead the pack in terms of number of biotech VC investments made in 2020, followed by RA Capital and Cormorant.  According to BioCentury’s BCIQ database, the top 50 VCs by number...

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures,...

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...

Crossover investors supplied Beam Therapeutics Inc. (NASDAQ:BEAM) with $260 million in a private placement early Tuesday, purchasing 2.8 million shares at $93. The price is an 18% discount to Beam’s closing price Friday of $113.04....

Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine company as an adviser. MacDonald was...

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...

FDA granted accelerated approval to Darzalex Faspro daratumumab/hyaluronidase-fihj from Johnson & Johnson (NYSE:JNJ) and Genmab A/S (CSE:GMAB; NASDAQ:GMAB) to treat newly diagnosed light-chain amyloidosis. It is the first and only therapy for the indication, according to Genmab,...